23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million

The New York Times – Business:

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.

This post first appeared in The New York Times – Business. Read the original article.